DiaMedica Therapeutics Inc. (DMAC)
NASDAQ: DMAC · Real-Time Price · USD
9.36
+0.32 (3.54%)
At close: Nov 6, 2026, 4:00 PM EST
9.52
+0.16 (1.71%)
After-hours: Nov 6, 2026, 4:22 PM EST
DiaMedica Therapeutics Employees
DiaMedica Therapeutics had 35 employees as of December 31, 2025. The number of employees increased by 7 or 25.00% compared to the previous year. That makes DiaMedica Therapeutics the 36,504th largest employer in the world and 5,021st in the United States.
Employees
35
Change (1Y)
7
Growth (1Y)
25.00%
Revenue / Employee
n/a
Profits / Employee
-$1,072,600
Market Cap
504.74M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 35 | 7 | 25.00% | 35 | 0 |
| Dec 31, 2024 | 28 | 9 | 47.37% | 27 | 1 |
| Dec 31, 2023 | 19 | 3 | 18.75% | 18 | 1 |
| Dec 31, 2022 | 16 | 1 | 6.67% | 16 | 0 |
| Dec 31, 2021 | 15 | 4 | 36.36% | 14 | 1 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| MiMedx Group | 808 |
| Gyre Therapeutics | 625 |
| Valneva SE | 620 |
| REGENXBIO | 371 |
| Capricor Therapeutics | 231 |
| Neurogene | 131 |
| CytomX Therapeutics | 69 |
| Monopar Therapeutics | 22 |
DMAC News
- 3 days ago - DiaMedica Therapeutics to Report Third Quarter 2026 Financial Results and Provide a Business Update November 13, 2026 - Business Wire
- 17 days ago - DiaMedica announces enrollment of 200th patient in ReMEDy2 Phase 2/3 trial - TheFly
- 17 days ago - DiaMedica Therapeutics Announces Enrollment of 200th Patient in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial - Business Wire
- 20 days ago - DiaMedica Therapeutics provides update on FGR trial at KOL event - TheFly
- 20 days ago - DiaMedica Therapeutics Provides Update on Fetal Growth Restriction Key Opinion Leader Webinar - Business Wire
- 5 weeks ago - DiaMedica Therapeutics Announces Key Opinion Leader Webinar on DM199 for Fetal Growth Restriction Featuring Early Phase 2 FGR Results - Business Wire
- 2 months ago - DiaMedica Therapeutics to Participate in Upcoming September Investor Conferences - Business Wire
- 2 months ago - DiaMedica Therapeutics Earnings Call Transcript: Q2 2026 - Transcripts